CD47 and myelodysplastic syndrome: Supported by pre-clinical data demonstrating robust anti-cancer activity in AML and MDS by anti-CD47 antibody, clinical trials using Hu5F9-G4 (magrolimab), in combination with azacitidine demonstrated exciting results in both intermediate to very high risk MDS patients and in untreated AML patients.